MediQuest Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Bothell WA United States (1994)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2004
NCT00253331
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

amphimatrix (2 trials)

nitroglycerin (transderm-nitro) (9 trials)

Drugs in Phase 2 Trials (3)

naftifine (naftin) (1 trial)

naltrexone (revia) (1 trial)

terbinafine (lamisil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 3)

Neoplasm Metastasis (Phase 3)

Onychomycosis (Phase 2)

Psoriasis (Phase 2)

Raynaud Disease (Phase 3)

Scleroderma, Diffuse (Phase 3)

Scleroderma, Systemic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5